dr. reddys laboratories ltd - RDY

RDY

Close Chg Chg %
14.65 0.61 4.16%

Closed Market

15.26

+0.61 (4.16%)

Volume: 4.62M

Last Updated:

Jun 25, 2026, 3:59 PM EDT

Company Overview: dr. reddys laboratories ltd - RDY

RDY Key Data

Open

$14.66

Day Range

14.62 - 15.27

52 Week Range

12.19 - 15.56

Market Cap

$12.21B

Shares Outstanding

832.66M

Public Float

832.66M

Beta

0.27

Rev. Per Employee

N/A

P/E Ratio

25.16

EPS

$0.59

Yield

48.77%

Dividend

$0.06

EX-DIVIDEND DATE

Jul 24, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

2.01M

 

RDY Performance

1 Week
 
14.75%
 
1 Month
 
12.13%
 
3 Months
 
13.13%
 
1 Year
 
1.19%
 
5 Years
 
6.06%
 

RDY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 38
Full Ratings ➔

About dr. reddys laboratories ltd - RDY

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment refers to the manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

RDY At a Glance

Dr. Reddy's Laboratories Ltd.
Door No. 8-2-337
Hyderabad, Telangana 500034
Phone 91-40-49002900 Revenue 3.80B
Industry Pharmaceuticals: Major Net Income 484.96M
Sector Health Technology Employees N/A
Fiscal Year-end 03 / 2027
View SEC Filings

RDY Valuation

P/E Current 25.163
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 23.773
Price to Sales Ratio N/A
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA N/A
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

RDY Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover 3.563
Total Asset Turnover 0.64

RDY Liquidity

Current Ratio 1.802
Quick Ratio 1.345
Cash Ratio 0.524

RDY Profitability

Gross Margin 52.768
Operating Margin 13.825
Pretax Margin 16.278
Net Margin 12.756
Return on Assets 8.167
Return on Equity 12.315
Return on Total Capital 10.123
Return on Invested Capital 11.979

RDY Capital Structure

Total Debt to Total Equity 20.511
Total Debt to Total Capital 17.02
Total Debt to Total Assets 13.35
Long-Term Debt to Equity 3.236
Long-Term Debt to Total Capital 2.685
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Dr. Reddys Laboratories Ltd - RDY

Collapse All in section
All values USD millions. 2023 2024 2025 2026 5-year trend
Sales/Revenue
3.06B 3.37B 3.85B 3.80B
Sales Growth
+6.35% +10.20% +14.18% -1.26%
Cost of Goods Sold (COGS) incl D&A
1.41B 1.49B 1.72B 1.80B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
157.27M 179.27M 201.76M 233.21M
Depreciation
107.22M 115.68M 124.25M 142.84M
Amortization of Intangibles
50.04M 63.60M 77.51M 90.37M
COGS Growth
-1.79% +6.15% +14.86% +4.67%
Gross Income
1.65B 1.88B 2.13B 2.01B
Gross Income Growth
+14.41% +13.64% +13.64% -6.02%
Gross Profit Margin
+54.02% +55.70% +55.44% +52.77%
2023 2024 2025 2026 5-year trend
SG&A Expense
1.01B 1.11B 1.32B 1.48B
Research & Development
228.55M 262.14M 307.92M 272.28M
Other SG&A
778.09M 848.89M 1.01B 1.21B
SGA Growth
+2.23% +10.37% +18.49% +12.47%
Other Operating Expense
- (3.48M) (4.08M) (3.82M)
Unusual Expense
8.70M 36.24K 20.02M 23.98M
EBIT after Unusual Expense
641.17M 771.50M 802.02M 501.64M
Non Operating Income/Expense
123.31M 115.55M 137.06M 159.54M
Non-Operating Interest Income
14.69M 27.52M 31.66M 89.07M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
17.77M 20.67M 33.46M 42.31M
Interest Expense Growth
+38.22% +16.29% +61.89% +26.43%
Gross Interest Expense
24.98M 31.71M 47.86M 42.31M
Interest Capitalized
- 7.21M 11.04M 14.39M
Pretax Income
746.71M 866.39M 905.62M 618.88M
Pretax Income Growth
+76.08% +16.03% +4.53% -31.66%
Pretax Margin
+24.40% +25.69% +23.52% +16.28%
Income Tax
190.42M 195.52M 231.10M 139.78M
Income Tax - Current - Domestic
- 109.12M 167.59M 211.82M
Income Tax - Current - Foreign
- 50.90M 67.45M 55.26M
Income Tax - Deferred - Domestic
- 48.43M 11.69M (12.70M)
Income Tax - Deferred - Foreign
- (18.03M) (51.22M) (23.28M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
560.90M 672.64M 677.08M 480.61M
Minority Interest Expense
- - 8.29M (4.35M)
-
Net Income
560.90M 672.64M 668.79M 484.96M
Net Income Growth
+77.31% +19.92% -0.57% -27.49%
Net Margin Growth
+18.33% +19.95% +17.37% +12.76%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
560.90M 672.64M 668.79M 484.96M
Preferred Dividends
- - - -
-
Net Income Available to Common
560.90M 672.64M 668.79M 484.96M
EPS (Basic)
0.6756 0.8085 0.8029 0.5826
EPS (Basic) Growth
+77.14% +19.67% -0.69% -27.44%
Basic Shares Outstanding
- 830.17M 831.97M 832.95M
EPS (Diluted)
0.6742 0.807 0.8017 0.582
EPS (Diluted) Growth
+77.28% +19.70% -0.66% -27.40%
Diluted Shares Outstanding
- 831.94M 833.54M 834.18M
EBITDA
807.14M 950.82M 1.02B 758.83M
EBITDA Growth
+29.86% +17.80% +7.68% -25.88%
EBITDA Margin
+26.38% +28.20% +26.59% +19.96%

Snapshot

Average Recommendation HOLD Average Target Price 13.972
Number of Ratings 38 Current Quarters Estimate 0.10
FY Report Date 06 / 2026 Current Year's Estimate 0.536
Last Quarter’s Earnings 0.028 Median PE on CY Estimate N/A
Year Ago Earnings 0.538 Next Fiscal Year Estimate 0.662
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 32 32
Mean Estimate 0.10 0.12 0.54 0.66
High Estimates 0.13 0.14 0.66 0.83
Low Estimate 0.08 0.11 0.43 0.54
Coefficient of Variance 26.43 12.75 11.42 11.28

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 12 12
OVERWEIGHT 4 4 2
HOLD 11 11 11
UNDERWEIGHT 3 3 5
SELL 7 7 6
MEAN Hold Hold Hold

Dr. Reddys Laboratories Ltd in the News